Actively Recruiting
Study of Intravenous Calcitonin Gene-Related Peptide to Trigger Migraine Aura in Adults with Migraine with Aura
Led by Danish Headache Center · Updated on 2025-08-06
21
Participants Needed
1
Research Sites
30 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are investigating whether administration of calcitonin gene-related peptide CGRP, an important neuropeptide involved in migraine, can trigger migraine aura in people diagnosed with migraine with aura. This study aims to confirm prior findings that CGRP can cause aura attacks despite limited ability to cross the blood-brain barrier, suggesting a role of trigeminovascular activation in migraine aura. The trial is randomized, double-blind, and placebo-controlled to validate this effect and eliminate placebo influence, potentially influencing future migraine treatments. Participants will receive either a continuous intravenous infusion of CGRP at 1.5 micrograms per minute for 60 minutes or a placebo infusion of isotonic saline over the same duration. The study has two groups one receiving CGRP and the other receiving placebo, both administered by intravenous infusion. The trial begins with screening and continues with the infusion on the experimental day under close monitoring. During the study, participants are monitored for migraine attacks with aura and without aura over a 12-hour period after infusion. Researchers will assess headache intensity scores and record the incidence of migraine attacks. Safety is closely observed, and participants will provide informed consent before starting. The study runs until late 2026, with participation lasting through screening, infusion, and post-infusion monitoring periods.
CONDITIONS
Brief Title
Induction of Migraine Attacks With Aura Using Calcitonin Gene-Related Peptide
Research Team
H
Haidar Al-Khazali, MD
H
Hakan Ashina, MD, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here